Independent Study Conducted at Boston Children's Hospital, Harvard Medical School, Shows Potential Utility of Jaguar Health's Crofelemer for Treatment of MVID, a Rare Childhood DiseaseAccesswire • 10/19/23
Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company's FDA-Approved Prescription DrugAccesswire • 10/18/23
Jaguar Health to Present October 17 at the Lytham Partners Fall 2023 Investor Conference and October 18 at the BIO Investor ForumAccesswire • 10/12/23
Jaguar Animal Health Exhibiting at October 12-14 VCS Annual Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in DogsAccesswire • 10/10/23
Jaguar Health to Present October 3 at LD Micro's Main Event Investor Conference, and on October 5 at the Global Capital Network Investor ConferenceAccesswire • 09/28/23
Jaguar Health Launches TikTok and Instagram Contest to Raise Awareness About Common Yet Barely Addressed Health Condition: Surprise DiarrheaAccesswire • 09/27/23
Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and SurvivorsAccesswire • 09/26/23
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHDAccesswire • 09/21/23
Filament Health's Magdalena Biosciences JV with Jaguar Health completes import of coca leaf from PeruProactive Investors • 09/20/23
Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment ConferenceAccesswire • 09/14/23
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)Accesswire • 09/13/23
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related DiarrheaAccesswire • 09/12/23
Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth ConferenceAccesswire • 09/11/23
Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs CommitteeAccesswire • 09/07/23
The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease IndicationsAccesswire • 08/30/23
Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment ConferenceAccesswire • 08/28/23
Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement CampaignAccesswire • 08/24/23
Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related DiarrheaAccesswire • 08/17/23
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment InterruptionAccesswire • 08/16/23
Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate UpdatesAccesswire • 08/10/23
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related DiarrheaAccesswire • 08/09/23
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion DiseaseAccesswire • 08/08/23
Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced DiarrheaAccesswire • 08/07/23
